



# Wilson Aarhus

**2-5 May 2024**  
**Final Program**

**Thursday May 2**

19.00-22.00 Welcome dinner at the venue Comwell, Værkmestergade 2, DK-8000 Aarhus C

**Friday May 3**

Morning

9.00 Welcome *President, Peter Ott (Aarhus)*

**Session I: Important stuff***Chairs: Thomas Sandahl, Michael Schilsky*

9.15 Search for evidence in WD *Piotr Socha (Warsaw)*

9.35 WD; What constitutes a cure and how do we know we are there? *Michael Schilsky (New Haven)*

9.50 Mitochondria in WD: relevance in pathophysiology, diagnosis and monitoring *Eve Roberts (Toronto)*

10.10 How does copper get in and out of the brain? *Svetlana Lutsenko (Baltimore)*

10.30 Coffee break

**Session II: Neurologic I***Chairs: Aurélie Poujois, Petr Dusek*

11.00 Markers of neurological damage, can they be used and what about CSF copper? *Oliver Bandmann (Sheffield)*

11.20 Difficulties in the early diagnosis of WD *Anna Czlonkowska (Warsaw)*

11.40 Early neurological worsening in WD - the current knowledge *Tomasz Litwin (Warsaw)*

12.00 Abstract 4: Can outcome of chelation be predicted? *Moinak Sen Sarma (Lucknow)*

12.20 Abstract 34: Coronary microvascular dysfunction in WD *Andreas Kindmark (Uppsala)*

12.35 Lunch

**Friday May 3**  
Afternoon

**Session III: Neurologic II**

*Chairs: Tomasz Litwin, Oliver Bandmann*

13.30	Cognitive impairment in WD	<i>Sam Shribman (London)</i>
13.50	Sleep disturbances in WD	<i>Valérie Cochen De Cock (Montpellier)</i>
14.05	Functional MRI and other MR modalities to diagnose and understand WD	<i>Sule Tinaz (New Haven)</i>
14.25	Disturbances of the olfactory function in WD	<i>Jan Bembenek (Warsaw)</i>
14.40	Abstract 36: Optical Coherence Tomography as a Marker of Neurodegeneration in WD	<i>Emily Steinkohl (Aarhus)</i>

**Session IV: Poster session**

14.55 Poster viewing and coffee break

**Session V: Hepatic**

*Chairs: Aftab Ala, Zoe Mariño*

15.55	Mechanisms of hepatic injury in WD	<i>Valentina Medici (Sacramento)</i>
16.15	Nuclear receptors in WD	<i>Clavia Ruth Wooton-Kee (Houston)</i>
16.30	Portal hypertension and its prognostic implications in patients with WD	<i>Albert Stättermayer (Vienna)</i>
16.45	Metallothionein: a game changer in histopathological diagnosis of WD	<i>Karl Heinz Weiss (Heidelberg)</i>
17.00	Abstract 29: Liver stiffness measurement in WD	<i>Rodolphe Sobesky (Paris)</i>
17.15	End of day	
19.00	Dinner at Smedien, Værkmestergade 7, DK-8000 Aarhus C	

**Saturday May 4**  
Morning

**Session VI: Basic science**

*Chairs: Hans Zischka, Svetlana Lutsenko*

9.00	The importance of autophagy in WD	<i>Roman Polishchuk (Pozzuoli)</i>
9.20	Copper metabolism and possibilities for its regulation	<i>Peep Palumaa (Tallinn)</i>
9.35	DNA damage pathways and the contribution of arsenic on copper toxicity in ATP7B <sup>-/-</sup> mice	<i>Sanjeev Gupta (Bronx)</i>
9.50	Abstract 6: $\alpha$ -lipoic acid reverses consequences of copper toxicity in a cellular model of WD	<i>Ekaterina Kabin (Tallinn)</i>
10.10	Abstract 11: Copper impairs the intestinal barrier integrity in WD	<i>Adriana Fontes (Neuherberg)</i>
10.25	Abstract 2: Copper transporter CTR1 (slc31a1) in model systems	<i>Stephen Kaler (Columbus)</i>
10.40	Coffee break	

**Session VII: Genetics**

*Chairs: Roman Polishchuk, Lisbeth Birk Møller*

11.10	Genotype-phenotype – any news?	<i>Anil Dhawan (London)</i>
11.30	Lessons from genetics after the Spanish National Registry (AEEH)	<i>Luis García-Villarreal (Las Palmas)</i>
11.45	Functional analysis of ATP7B mutations	<i>Nishka Kishore (Toronto)</i>
12.05	Screening for WD using the APT7B protein	<i>Sihoun Hahn (Seattle)</i>
12.25	Abstract 12: CRISPR/CAS-9 correction of WD point mutation in IPS cell-derived hepatocyte-like cells	<i>Vanessa Sandfort (Münster)</i>
12.40	Lunch	

**Saturday May 4**  
Afternoon

**Session VIII: Monitoring**

*Chairs: Seema Alam, Anil Dhawan*

13.40	Rhonda's Story of WD	<i>Rhonda Rowland (New York)</i>
14.00	Accurate NCC: A New Biomarker for WD	<i>Chris Harrington (Guildford)</i>
14.20	NCC and UCE. Lessons from the Chelate trial	<i>Peter Ott (Aarhus)</i>
14.35	New Data on CuExc from France	<i>Clément Desjardins (Paris)</i>
14.50	Skin changes and its implications in WD	<i>Aftab Ala (London)</i>
15.05	Coffee break	

**Session IX: Registries. The past, the present and the future.**

*Chairs: Albert Stättermayer, Anna Członkowska, Piotr Socha*

Several WD registries are now active or being developed: National databases in Poland, France, Spain, England, Austria and Denmark; large local databases, such as in Heidelberg; and newer transnational databases such as the Yale Registry. In this section of the Aarhus Wilson Meeting, we will include a discussion about the purpose of registries in WD, the most important data to include, and other key issues related to establishing and maintaining a registry.

15.35	Introduction	<i>Peter Ott (Aarhus)</i>
15.50	<b>The Past:</b> The rise and decline of EuroWilson	<i>Anil Dhawan (London)</i>
16.05	<b>The Present:</b> What are the most burning questions to be answered by registries?	<i>Michael Schilsky (New Haven)</i>
16.20	Core hepatologic data	<i>Zoe Mariño (Barcelona)</i>
16.35	Core neurologic data	<i>Aurélia Poujois (Paris)</i>
16.50	Core psychiatry	<i>Paula Zimbrea (New Haven)</i>
17.05	Present low hanging fruits	<i>Karl Heinz Weiss (Heidelberg)</i>
17.20	<b>The Future:</b> Potential of AI and Big Data	<i>Rafał Józwiak (Warsaw)</i>
17.35	End of day	
19.00	Dinner at Havnær, Dagmar Petersens Gade 119, DK-8000 Aarhus C	

**Sunday May 5**

Morning

**Session X: Monitoring**
*Chairs: Karl Heinz Weiss, Valentina Medici*

9.00	NCC in ALF	<i>Thomas Sandahl (Aarhus)</i>
9.15	Standardized U-Cu off and on treatment	<i>Verena Aliane (Rotterdam)</i>
9.30	Exchangeable copper in a real clinical setting	<i>Zoe Mariño (Barcelona)</i>
9.45	Plasmapheresis in the Management of Fulminant WD	<i>Seema Alam (New Delhi)</i>
10.00	Abstract 35: Population biobank as a multilayer display of rare disease: from hidden cases to targeted treatment	<i>Miriam Nurm (Tartu)</i>
10.15	Coffee break	

**Session XI: Upcoming therapies and future perspectives**
*Chairs: Peter Ott, Eve Roberts*

10.45	Dose equivalence - D-Pen and TETA-4	<i>Aurélia Poujois (Paris)</i>
11.05	Hurdles and opportunities in gene-based therapies for WD	<i>Pasquale Piccolo (Pozzuoli)</i>
11.20	Abstract 7: Molecular trafficking of the copper-chelator ARBM-101	<i>So-Young Eun (Seoul)</i>
11.35	Methanobactin in an animal model of end stage liver disease	<i>Hans Zischka (Neuherberg)</i>
11.55	Future perspectives	<i>Fred Askari (Ann Arbor)</i>
12.10	Closing remarks	<i>Peter Ott (Aarhus)</i>
12.15	Lunch	
13.30	Departure	